Jane Kriengkauykiat

Use of an Efflux Pump Inhibitor To Determine the Prevalence of Efflux Pump-Mediated Fluoroquinolone Resistance and Multidrug Resistance in <i>Pseudomonas aeruginosa</i>

Jane Kriengkauykiat, Edith Porter, Olga Lomovskaya et al. · Antimicrobial Agents and Chemotherapy · 2005 · 139 citations · Full text

Multidrug Resistance, Antimicrobial Chemotherapy, Antibiotic Resistance +16

Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis

Paul M. Beringer, Kitty My Tu Huynh, Jane Kriengkauykiat et al. · Antimicrobial Agents and Chemotherapy · 2005 · 57 citations · Full text

Antimicrobial Susceptibility, Health Sciences, Antibiotics +13

Lack of Effect of P‐glycoprotein Inhibition on Renal Clearance of Dicloxacillin in Patients with Cystic Fibrosis

Paul M. Beringer, Jane Kriengkauykiat, Xiyun Zhang et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2008 · 28 citations

The impact of an automated antibiotic stewardship intervention for the management of Staphylococcus aureus bacteraemia utilizing the electronic health record

Amy L. Brotherton, Saira Rab, Sheetal Kandiah et al. · Journal of Antimicrobial Chemotherapy · 2019 · 12 citations

Breakthrough Invasive Fungal Infections in Patients With Hematologic Malignancy (HM) and Hematopoietic Cell Transplantation (HCT) Receiving Isavuconazole for Empiric or Directed Antifungal Therapy

Sanjeet Dadwal, Jane Kriengkauykiat, Bernard Tegtmeier et al. · Open Forum Infectious Diseases · 2016 · 11 citations · Full text

Hematologic Malignancy, Directed Antifungal Therapy, Antifungal Agent +6